전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved60 programs
AntibodyLimited DatastaleUniversity of Colorado, DenverPhase 1

IPI-926 and Cetuximab (IPI-926 and Cetuximab)

Recurrent Head and Neck Cancer · Recurrent Head and Neck Cancer

#RecurrentHeadandNeckCancer#Antibody#Phase1#monoclonal-antibody#University
Trials 1Status Active
AntibodyLimited DatastaleGroupe Oncologie Radiotherapie …Phase 3

Ligufalimab (Ligufalimab)

Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) · Squamous Cell Carcinoma Head and Neck Ca

#SquamousCellCarcinomaHeadandNeck#Antibody#Phase3#monoclonal-antibody#Groupe
Trials 1Status Recruiting
ADCLimited DatastaleDongguan People's HospitalPhase 2

MRG003 (MRG003, Becotatug vedotin, MRG003 (Becotatug vedotin) and Toripalimab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#ADC#Phase2#antibody-drug-conjugate#Dongguan
Trials 1Status Recruiting
AntibodyLimited DatastaleLei LiuPhase 2

MRG003 combined with Pucotenlimab (MRG003 combined with Pucotenlimab)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Lei
Trials 1Status Recruiting
AntibodyLimited DatastaleLei LiuPhase 2

MRG003 combined with Pucotenlimab+Cisplatin (MRG003 combined with Pucotenlimab+Cisplatin)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Lei
Trials 1Status Recruiting
ADCLimited DatastaleBioAtla, Inc.Phase 2

Ozuriftamab Vedotin (Ozuriftamab Vedotin)

Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck · Head and Neck Cancer

#HeadandNeckCancer#ADC#Phase2#antibody-drug-conjugate#SquamousCellCarcinomaofHeadandNe+1
Trials 1Status Active
AntibodyLimited DatastaleMerckPhase 3

pembrolizumab (Keytruda, PD-1 mAb, Pembrolizumab/Finotonlimab, PD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy)

Squamous Cell Carcinoma of Head and Neck · PD-1

#PD-1#Antibody#Phase3#monoclonal-antibody#SquamousCellCarcinomaofHeadandNe+1
Trials 1Status Recruiting
AntibodyLimited DatastaleMerus B.V.Phase 3

Petosemtamab (Petosemtamab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Merus
Trials 1Status Recruiting
AntibodyLimited DatastaleLG ChemPhase 1

atezolizumab (Tecentriq, Phase 1b: LB-LR1109 and Atezolizumab)

Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC) · Non-small Cell Lung Cancer(NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase1#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAssociazione Volontari Pazienti…Phase 3

RT+CETUXIMAB (RT+CETUXIMAB)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Associazione
Trials 1Status Active
ADCLimited DatastaleBiying ChenPhase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor)

Recurrent or Metastatic Head and Neck Carcinoma · MET

#MET#ADC#Phase2#antibody-drug-conjugate#RecurrentorMetastaticHeadandNeck+1
Trials 1Status Recruiting
AntibodyLimited DatastalePresage BiosciencesPhase 1

TAK-981 + Avelumab (TAK-981 + Avelumab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase1#monoclonal-antibody#Presage
Trials 1Status Active
AntibodyLimited DatastalePresage BiosciencesPhase 1

TAK-981 + Cetuximab (TAK-981 + Cetuximab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase1#monoclonal-antibody#Presage
Trials 1Status Active
AntibodyLimited DatastaleTJ Biopharma Co., Ltd.Phase 2

pembrolizumab (Keytruda, TJ107 +Pembrolizumab)

Triple-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#Antibody#Phase2#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

TPF, radiotherapy and cetuximab (TPF, radiotherapy and cetuximab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleWest China HospitalPhase 2

Tagitanlimab (Tagitanlimab)

Resectable Head and Neck Squamous Cell Carcinoma · Resectable Head and Neck Squamous Cell C

#ResectableHeadandNeckSquamousCel#Antibody#Phase2#monoclonal-antibody#West
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab+cetuximab (Toripalimab+cetuximab)

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma · Patients With Locally Recurrent Resectab

#PatientsWithLocallyRecurrentRese#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleXencor, Inc.Phase 1

XmAb®808 (XmAb®808)

Head and Neck Squamous Cell Carcinoma; Melanoma Excluding Uveal Melanoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#MelanomaExcludingUvealMelanoma+1
Trials 1Status Active
AntibodyLimited DatastaleVaccinex Inc.Phase 2

pembrolizumab (Keytruda, pepinemab + pembrolizumab)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) · Recurrent/Metastatic Squamous Cell Carci

#RecurrentMetastaticSquamousCellC#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 2

treme (tremelimumab, tremelimumab (treme))

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck · Advanced Solid Tumors & Metastatic Squam

#AdvancedSolidTumorsMetastaticSqu#Antibody#Phase2#monoclonal-antibody#AstraZeneca
Trials 1Status Active

3 / 3 pages

← PreviousNext →